# Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma

Source: https://onco.cc/trials/nct07845266/  
OnCo record `nct07845266` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of GKL-006 Injection run by Beijing Gene Key Life Technology Co., Ltd, completed.

## Summary

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma is a phase 1 interventional study registered as NCT07845266 by Beijing Gene Key Life Technology Co., Ltd, with 13 participants enrolled, started 2024-04-16. Conditions recorded: Hepatocellular Carcinoma (HCC) and Unresectable Hepatocellular Carcinoma. Interventions recorded: GKL-006 Injection and transarterial chemoembolization.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07845266
- Phase: 1
- Setting: A Phase 1, Open-label, Controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
- Sponsor: Beijing Gene Key Life Technology Co., Ltd
- Enrolled: 13

## Sources

- ClinicalTrials.gov NCT07845266: https://clinicaltrials.gov/study/NCT07845266

## Connected records

- cancers: [Advanced hepatocellular carcinoma (BCLC C)](https://onco.cc/cancers/hcc-advanced/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [GKL-006 Injection](https://onco.cc/drugs/gkl-006/)
- companies: [Beijing Gene Key Life Technology](https://onco.cc/companies/beijing-gene-key-life-technology/)

---
JSON: https://onco.cc/api/v1/entities/nct07845266.json